News
Enara Bio to present progress in Dark Antigen™ research at upcoming Neoantigen-Based Therapies Summit
Enara Bio, a biotechnology company leveraging its proprietary T-cell/T-cell receptor (TCR) discovery and Dark Antigen™ platforms to deliver targeted cancer immunotherapies, will present at the 5th Neoantigen Based Therapies Summit on November 5.
Ervaxx rebrands as Enara Bio to reflect a broader emphasis on the discovery and development of novel TCR-based cancer immunotherapies
This new name reflects the company’s expanded product discovery and development strategy beyond its initial focus on endogenous retroviral (ERV) antigens for the development of cancer vaccines (hence “Ervaxx”).
Ervaxx and Cardiff University enter collaboration to develop novel
T-cell and T-cell receptor-based immunotherapeutics targeting
Dark Antigens™
Collaboration also focuses on exciting research published earlier this week in Nature Immunology identifying MR1 as a target for novel anti-cancer immunotherapies
Ervaxx presents research identifying melanoma-specific Dark Antigens™ at SITC 2019.
CSO Dr. Ray Jupp presented data on Ervaxx’s lead program at the 34th Society for Immunotherapy of Cancer (SITC) annual meeting in National Harbor, MD, USA on Saturday 9th November 2019.
Ervaxx launches to pioneer the use of Dark Antigens™ for the development of off-the-shelf cancer vaccines and T-cell receptor- based immunotherapies
Ervaxx coincides its launch with the presentation of new research to identify novel melanoma-specific Dark Antigens by application of its novel EDAPT™ platform at The Society for Immunotherapy of Cancer 34th Annual Meeting (SITC).